We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amarin (AMRN) Outpaces Stock Market Gains: What You Should Know
Read MoreHide Full Article
In the latest trading session, Amarin (AMRN - Free Report) closed at $19.75, marking a +0.71% move from the previous day. This move outpaced the S&P 500's daily gain of 0.46%. Meanwhile, the Dow gained 0.15%, and the Nasdaq, a tech-heavy index, added 0.59%.
Coming into today, shares of the biopharmaceutical company had lost 7.93% in the past month. In that same time, the Medical sector gained 0.72%, while the S&P 500 gained 3.24%.
AMRN will be looking to display strength as it nears its next earnings release. In that report, analysts expect AMRN to post earnings of -$0.06 per share. This would mark year-over-year growth of 14.29%. Meanwhile, our latest consensus estimate is calling for revenue of $72.23 million, up 64.46% from the prior-year quarter.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of -$0.07 per share and revenue of $370.57 million. These totals would mark changes of +78.79% and +61.67%, respectively, from last year.
Any recent changes to analyst estimates for AMRN should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 6.73% lower. AMRN is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 78, which puts it in the top 31% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow AMRN in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Amarin (AMRN) Outpaces Stock Market Gains: What You Should Know
In the latest trading session, Amarin (AMRN - Free Report) closed at $19.75, marking a +0.71% move from the previous day. This move outpaced the S&P 500's daily gain of 0.46%. Meanwhile, the Dow gained 0.15%, and the Nasdaq, a tech-heavy index, added 0.59%.
Coming into today, shares of the biopharmaceutical company had lost 7.93% in the past month. In that same time, the Medical sector gained 0.72%, while the S&P 500 gained 3.24%.
AMRN will be looking to display strength as it nears its next earnings release. In that report, analysts expect AMRN to post earnings of -$0.06 per share. This would mark year-over-year growth of 14.29%. Meanwhile, our latest consensus estimate is calling for revenue of $72.23 million, up 64.46% from the prior-year quarter.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of -$0.07 per share and revenue of $370.57 million. These totals would mark changes of +78.79% and +61.67%, respectively, from last year.
Any recent changes to analyst estimates for AMRN should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 6.73% lower. AMRN is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 78, which puts it in the top 31% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow AMRN in the coming trading sessions, be sure to utilize Zacks.com.